Nginache Nampota-Nkomba, Osward M. Nyirenda, Victoria Mapemba, Rhoda Masonga, Priyanka D. Patel, Theresa Misiri, Felistas Mwakiseghile, Richard Wachepa, John M. Ndaferankhande, Bright Lipenga, Pratiksha Patel, Happy Banda, Jennifer Oshinsky, Marcela F. Pasetti, Robert S. Heyderman, Leslie P. Jamka, Divya Hosangadi, Shrimati Datta, Melita A. Gordon, Kathleen M. Neuzil, Matthew B. Laurens
{"title":"未感染艾滋病毒和未感染艾滋病毒的马拉维儿童接种单剂和双剂伤寒结合疫苗的安全性和免疫原性","authors":"Nginache Nampota-Nkomba, Osward M. Nyirenda, Victoria Mapemba, Rhoda Masonga, Priyanka D. Patel, Theresa Misiri, Felistas Mwakiseghile, Richard Wachepa, John M. Ndaferankhande, Bright Lipenga, Pratiksha Patel, Happy Banda, Jennifer Oshinsky, Marcela F. Pasetti, Robert S. Heyderman, Leslie P. Jamka, Divya Hosangadi, Shrimati Datta, Melita A. Gordon, Kathleen M. Neuzil, Matthew B. Laurens","doi":"10.1080/21645515.2024.2384760","DOIUrl":null,"url":null,"abstract":"Vaccine safety and immunogenicity data in human immunodeficiency virus (HIV)-exposed uninfected (HEU) children are important for decision-making in HIV and typhoid co-endemic countries. In an open-...","PeriodicalId":13058,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"26 1","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Single and two-dose typhoid conjugate vaccine safety and immunogenicity in HIV-exposed uninfected and HIV-unexposed uninfected Malawian children\",\"authors\":\"Nginache Nampota-Nkomba, Osward M. Nyirenda, Victoria Mapemba, Rhoda Masonga, Priyanka D. Patel, Theresa Misiri, Felistas Mwakiseghile, Richard Wachepa, John M. Ndaferankhande, Bright Lipenga, Pratiksha Patel, Happy Banda, Jennifer Oshinsky, Marcela F. Pasetti, Robert S. Heyderman, Leslie P. Jamka, Divya Hosangadi, Shrimati Datta, Melita A. Gordon, Kathleen M. Neuzil, Matthew B. Laurens\",\"doi\":\"10.1080/21645515.2024.2384760\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Vaccine safety and immunogenicity data in human immunodeficiency virus (HIV)-exposed uninfected (HEU) children are important for decision-making in HIV and typhoid co-endemic countries. In an open-...\",\"PeriodicalId\":13058,\"journal\":{\"name\":\"Human Vaccines & Immunotherapeutics\",\"volume\":\"26 1\",\"pages\":\"\"},\"PeriodicalIF\":4.8000,\"publicationDate\":\"2024-09-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Human Vaccines & Immunotherapeutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/21645515.2024.2384760\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Vaccines & Immunotherapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/21645515.2024.2384760","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
人类免疫缺陷病毒(HIV)暴露的未感染(HEU)儿童的疫苗安全性和免疫原性数据对于 HIV 和伤寒共同流行国家的决策非常重要。在一项开放性的研究中,我们发现了对未感染人类免疫缺陷病毒(HIV
Single and two-dose typhoid conjugate vaccine safety and immunogenicity in HIV-exposed uninfected and HIV-unexposed uninfected Malawian children
Vaccine safety and immunogenicity data in human immunodeficiency virus (HIV)-exposed uninfected (HEU) children are important for decision-making in HIV and typhoid co-endemic countries. In an open-...
期刊介绍:
(formerly Human Vaccines; issn 1554-8619)
Vaccine research and development is extending its reach beyond the prevention of bacterial or viral diseases. There are experimental vaccines for immunotherapeutic purposes and for applications outside of infectious diseases, in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s and addiction. Many of these vaccines and immunotherapeutics should become available in the next two decades, with consequent benefit for human health. Continued advancement in this field will benefit from a forum that can (A) help to promote interest by keeping investigators updated, and (B) enable an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines and immunotherapeutics.
Human Vaccines & Immunotherapeutics provides such a forum. It is published monthly in a format that is accessible to a wide international audience in the academic, industrial and public sectors.